Interim results from an open-label extension study of briakinumab for the treatment of moderate to severe psoriasis

被引：0
|
作者：
Langley, Richard G. [1 ]
Williams, David [2 ]
Papp, Kim [3 ]
Olds, Michele [2 ]
机构：
[1] Dalhousie Univ, Halifax, NS, Canada
[2] Abbott Labs, Abbott Pk, IL 60064 USA
[3] Prob Med Res, Waterloo, ON, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2012年 / 66卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB195 / AB195
页数：1
相关论文
共 50 条
  • [31] Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
    van de Kerkhof, P.
    Guenther, L.
    Gottlieb, A. B.
    Sebastian, M.
    Wu, J. J.
    Foley, P.
    Morita, A.
    Goldblum, O.
    Zhang, L.
    Erickson, J.
    Ball, S.
    Rich, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 477 - 482
  • [32] Infliximab for severe, treatment-resistant psoriasis: a prospective, open-label study
    Smith, C. H.
    Jackson, K.
    Bashir, S. J.
    Perez, A.
    Chew, A. L.
    Powell, A. M.
    Wain, M.
    Barker, J. N. W. N.
    BRITISH JOURNAL OF DERMATOLOGY, 2006, 155 (01) : 160 - 169
  • [33] ABP 501 Long-Term Safety/Efficacy: Interim Results from an Open-Label Extension Study
    Cohen, Stanley
    Pablos, Jose L.
    Zhang, Nan
    Rizzo, Warren
    Muller, Gerhard
    Padmanaban, Devi
    Kivitz, Alan
    Matsumoto, Alan K.
    Kaur, Primal
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [34] Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension
    Cork, M. J.
    Thaci, D.
    Eichenfield, L. F.
    Arkwright, P. D.
    Hultsch, T.
    Davis, J. D.
    Zhang, Y.
    Zhu, X.
    Chen, Z.
    Li, M.
    Ardeleanu, M.
    Teper, A.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Ruddy, M.
    Graham, N. M. H.
    Pirozzi, G.
    Stahl, N.
    DiCioccio, A. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 182 (01) : 85 - 96
  • [35] Long-term efficacy and safety of risankizumab (RZB) for the treatment of moderate to-severe plaque psoriasis: Interim analysis of results from the LIMMitless open-label extension trial beyond 4 years of follow-up
    Papp, Kim A.
    Lebwohl, Mark G.
    Puig, Lluis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB77 - AB77
  • [36] Laboratory safety of long-term dupilumab treatment in adults with moderate-to-severe atopic dermatitis: Results from an open-label extension (OLE) study
    Blauvelt, Andrew
    Wollenberg, Andreas
    Beck, Lisa A.
    Chen, Zhen
    Zhang, Meng
    Khokhar, Faisal A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB142 - AB142
  • [37] Interim analysis: Open-label extension study of leniolisib for patients with APDS
    Rao, V. Koneti
    Kulm, Elaine
    Sediva, Anna
    Plebani, Alessandro
    Schuetz, Catharina
    Shcherbina, Anna
    Dalm, Virgil A.
    Trizzino, Antonino
    Zharankova, Yulia
    Webster, Sharon
    Orpia, Alanvin
    Koeurorholz, Julia
    Lougaris, Vassilios
    Rodina, Yulia
    Radford, Kath
    Bradt, Jason
    Relan, Anurag
    Holland, Steven M.
    Lenardo, Michael J.
    Uzel, Gulbu
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (01) : 265 - 274.e9
  • [38] Agomelatine in pediatric patients with moderate to severe major depressive disorder: an open-label extension study
    Arango, Celso
    Fegert, Joerg M.
    Picarel-Blanchot, Francoise
    Marx, Ute
    Truffaut-Chalet, Lucie
    Penelaud, Pierre-Francois
    Buitelaar, Jan
    EUROPEAN CHILD & ADOLESCENT PSYCHIATRY, 2024,
  • [39] A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease
    Reisberg, B
    Doody, R
    Stöffler, A
    Schmitt, F
    Ferris, S
    Möbius, HJ
    ARCHIVES OF NEUROLOGY, 2006, 63 (01) : 49 - 54
  • [40] Etanercept in the treatment of psoriasis vulgaris: Results from an open-label 6-month study
    Stratigos, A. J.
    Avgerinou, G.
    Dessinioti, C.
    Antoniou, C.
    Stavropoulos, P. G.
    Katsambas, A. D.
    EADV: PROCEEDINGS OF THE 15TH CONGRESS OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2006, : 721 - +
12345